Evidence map›Paper›PMID 42254986›Full record

ArticleOpen medicine (Warsaw, Poland)2026

Immunoinformatics based design of a multiepitope vaccine targeting

Muhammad Naveed, Muhammad Toheed, Tariq Aziz, Muhammad Asim, Hafiz Muzzammel Rehman, Nausheen Nazir, Manal F Elkhadragy, Rania Ali El Hadi Mohamed, Ashwag Shami, Maher S Alwethaynani and 1 more

Abstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Muhammad NaveedDepartment of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore, Pakistan.ORCID https://orcid.org/0000-0002-4333-8226
Muhammad ToheedDepartment of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore, Pakistan.
Tariq AzizSchool of Biomedical Engineering, Shenzhen University, Shenzhen, Guangdong, China.
Muhammad AsimDepartment of Biotechnology, Faculty of Science and Technology, University of Central Punjab, Lahore, Pakistan.ORCID https://orcid.org/0009-0001-0997-7630
Hafiz Muzzammel RehmanSchool of Biochemistry & Biotechnology, University of the Punjab, Lahore, Pakistan.
Nausheen NazirDepartment of Biochemistry, University of Malakand, Chakdara, Pakistan.ORCID https://orcid.org/0000-0003-4289-3970
Manal F ElkhadragyDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Rania Ali El Hadi MohamedDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0003-2513-4710
Ashwag ShamiDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Maher S AlwethaynaniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh, Saudi Arabia.
Deema FallatahDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To design and computationally evaluate a multiepitope-based vaccine candidate targeting antigenic proteins of Methods: Three antigenic proteins, ATP-dependent zinc metalloprotease FtsH, signal peptidase I, and protein translocase subunit SecY, were selected based on antigenicity, non-allergenicity, and non-toxicity. B-cell and T-cell epitopes were predicted and screened for immunogenic potential and global population coverage. A multiepitope vaccine construct containing six MHC class I and six MHC class II epitopes was assembled using appropriate linkers and a beta-defensin-3 adjuvant. Structural modeling, molecular docking with Toll-like receptor 4 (TLR4), and molecular dynamics simulations were performed to assess structural behavior and receptor interactions. Codon optimization and Results: The final vaccine construct showed antigenicity with a VaxiJen score of 0.5666 and structural stability with an instability index of 32.50. Population coverage analysis indicated 93.20 % global coverage. Molecular docking and molecular dynamics simulations indicated stable interactions with TLR4. Codon optimization suggested improved translational compatibility in Conclusions: The computational analysis suggests that the designed multiepitope construct has characteristics associated with immunogenic potential and structural stability. Further experimental validation is required to confirm its biological efficacy.

Indexed as

immunoinformaticsmolecular dockingmolecular dynamics simulationmultiepitope vaccinerat-bite feverStreptobacillus moniliformis

Identifiers

PMID42254986
PMCPMC13238150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.